Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Ondansetron

Classification: A

Drug products: Ondansetron 2care4, Ondansetron Abacus Medicine, Ondansetron Accord, Ondansetron Alternova, Ondansetron Aristo, Ondansetron Aurobindo, Ondansetron B. Braun, Ondansetron Bluefish, Ondansetron Copyfarm, Ondansetron Ebb, Ondansetron EQL Pharma, Ondansetron Fresenius Kabi, Ondansetron Hameln, Ondansetron Hexal, Ondansetron Kalceks, Ondansetron Mylan, Ondansetron Nycomed, Ondansetron Orifarm, Ondansetron Sandoz, Ondansetron STADA, Ondansetron Teva, Ondansetron Vian, Setofilm, Zofran, Zofran munlöslig, Zofran Syrup, Zofran®, Zofran® munlöslig, Zofron munlöslig, Zotrix

ATC code: A04AA01

Substances: ondansetron, ondansetron hydrochloride, ondansetron hydrochloride dihydrate

Summary

Women have a slower excretion and higher bio availability and AUC after single dose ondansetrone. Women have more nausea and vomiting after surgery and chemo therapy compared to men. As with many other antiemetic drugs men have usually better effect of ondansetrone treatment.

Ondansetrone, particularly when administered IV in high doses is associated with QT prolongation on ECG and thus a risk of developing the serious arrhythmia “Torsade de Pointes” ventricular tachycardia. No difference in risk has been shown regarding ondansetrone but one risk factor of Torsade de Pointes is female sex.

Additional information

Pharmacokinetics and dosing

In a pharmacokinetic study of healthy volunteers with normal body weight (17 men, 17 women) divided in three age groups; 21-38 years; 61-74 years; and 75-82 years of age, AUC and Cmax values were higher in women than in men after a single oral dose of ondansetron. In women, clearance was found to be lower, oral bioavailability higher due to reduced first-pass uptake of parent drug, and apparent volume of distribution smaller than in men [1]. A cross over study between oral and rectal ondansetron (8 men, 8 women) found similar results with higher AUC and lower clearance in women for both administration forms [2]. Despite the pharmacokinetic differences of ondansetron, the clinical studies have shown effect with similar doses in men and women and no sex differentiation in dosing has been suggested by the manufacturer [3].

Effects

In an open prospective multicenter study of the effect on ondansetron on cisplatin-induced emesis and nausea (16 men, 76 women), 50% of the women had delayed emesis compared to 19% of the men. Treatment failure on worst day was 30% in women and 0% in men [4]. Similar results were found in another randomized study comparing the antiemetic effect after cisplatine induced nausea of ondansetron with metoclopramide+lorazepam (53 men, 68 women). Treatment success was found in 95% of men and 65% of women [5]. In a cross-over study of chemotherapy induced emesis (270 men, 130 women), women had less chance of complete recovery from emesis [6].

Adverse effects

Several studies have shown ondansetron to prolong the electric repolarization (QT-interval) in the heart, increasing the risk of ventrical arrhythmias [7-9]. In an observational study (17 men, 25 women) on QT-prolongation after ondansetron treatment of post-operative nausea, 9 men and 9 women had ondansetron-induced prolonged QTc-interval [7]. With a few exceptions all ondansetron induced Torsades de pointes have been associated with IV-administration of high doses [8-9]. A warning for 32 mg ondansetron IV has been issued by the FDA [9]. Among the known risk factors of drug induced ventrical arrhythmias are female sex, hypokalemia, bradycardia, and base line QT-prolongation [10].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2022-06-22

Date of litterature search: 2015-01-13

References

  1. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992;51:51-5. PubMed
  2. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;18:288-94. PubMed
  3. Zofran (ondansetron). Summary of Product Characteristics. Medical Products Agency; 2016.
  4. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450-7. PubMed
  5. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113:834-40. PubMed
  6. Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-5. PubMed
  7. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094-100. PubMed
  8. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19-25e6. PubMed
  9. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Food and Drug Administration [www]. [cited 2015-01-14]. Länk
  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22. PubMed
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Mia von Euler

Reviewed by: Karin Schenck-Gustafsson

Approved by: Karin Schenck-Gustafsson